A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06818812 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: INCB186748
DRUG: Cetuximab
DRUG: GEMNabP
DRUG: mFOLFIRINOX

Sponsor

Incyte Corporation